| Literature DB >> 31791284 |
Zhaoyu Gan1, Xiuhua Wu1, Zhongcheng Chen2, Yingtao Liao1, Yingdong Wu1, Zimeng He1, Zhihua Yang1, Qi Zhang3.
Abstract
BACKGROUND: Conclusions regarding the association between antithyroid antibodies or thyroid dysfunction and rapid cycling bipolar disorder (RCBD) have been conflicting. Previous studies suggest that the impact of antithyroid antibodies on mental wellbeing seems to be independent of thyroid function. Here, we investigated their independent association with RCBD in a large, well-defined population of bipolar disorder (BD).Entities:
Keywords: Anti-thyroiglobulin antibodies; Antithyroid peroxidase antibodies; Bipolar disorder; Rapid cycling; Thyroid dysfunction
Mesh:
Substances:
Year: 2019 PMID: 31791284 PMCID: PMC6889186 DOI: 10.1186/s12888-019-2354-6
Source DB: PubMed Journal: BMC Psychiatry ISSN: 1471-244X Impact factor: 3.630
The demographic and clinical characteristics of the subjects
| variables | RCa | NRC | Total |
|---|---|---|---|
| Age (mean ± SD) (year) | 28.2 ± 14.2 | 27.8 ± 10.6 | 27.5 ± 11.6 |
| Female [ | 31 (67.4%) | 175 (57.2%) | 206 (58.5%) |
| Years of education (mean ± SD) (year) | 12.0 ± 3.5 | 12.5 ± 3.3 | 12.4 ± 3.3 |
| Marriage status | |||
| Married [ | 14 (30.4%) | 95 (31.0%) | 109 (31.0%) |
| Single [ | 29 (63.0%) | 199 (65.0%) | 228 (64.8%) |
| Divorced [ | 3 (6.5%) | 11 (3.6%) | 14 (4.0%) |
| Widowed [ | 0 (0.0%) | 1 (0.3%) | 1 (0.3%) |
| Psychotic features [ | 9 (19.6%) | 66 (21.6%) | 75 (21.3%) |
| Atypical features | |||
| Increased appetite [ | 6 (13.0%) | 68 (22.9%) | 74 (21.7%) |
| Weight gain [ | 4 (8.7%) | 55 (18.5%) | 59 (17.3%) |
| Hypersomnia [ | 14 (30.4%) | 81 (27.3%) | 95 (27.0%) |
| Comorbidity of thyroid diseasesa | 5 (10.9%) | 14 (4.6%) | 19 (5.4%)b |
| Substance abuse [ | 2 (4.3%) | 22 (7.2%) | 24 (6.8%) |
| HAMD-17 total scores (mean ± SD) | 19.4 ± 7.6 | 18.7 ± 9.5 | 18.7 ± 9.2 |
| YMRS total scores (mean ± SD) | 8.3 ± 8.0 | 11.8 ± 10.5* | 11.3 ± 10.4 |
| BMI (mean ± SD) | 21.4 ± 3.5 | 21.8 ± 3.6 | 21.7 ± 3.5 |
| Current episode | |||
| remission | 3 (6.5%) | 28 (9.2%) | 31 (8.8%) |
| depressive | 27 (58.7%) | 144 (47.1%) | 171 (48.6%) |
| (hypo)manic | 1 (2.2%) | 29 (9.5%) | 30 (8.5%) |
| mixed | 15 (32.6%) | 105 (34.3%) | 120 (34.1%) |
| Duration of illness (mean ± SD) (year) | 5.1 ± 5.7 | 4.9 ± 6.0 | 4.8 ± 5.9 |
| Psychopharmaceutical treatment [ | 15 (32.6%) | 105 (34.3%) | 120 (34.1%) |
| Lithium [ | 2 (4.3%) | 19 (6.2%) | 21 (6.0%) |
| Anticonvulsants [ | 8 (17.4%) | 46 (15.1%) | 54 (15.3%)b |
| Antipsychotics [ | 10 (21.7%) | 80 (26.1%) | 90 (25.5%) c |
| Antidepressants [ | 9 (19.6%) | 38 (12.4%) | 47 (13.4%)d |
*p < 0.05; RC: rapid cycling; NRC: non-rapid cycling; HAMD-17: 17-item Hamilton Depression Scale; YMRS: Young Mania Rating Scale
aIncluding 9 with history of Grave’s diseases, 3 with thyroiditis, 2 with thyroid cyst, 2 with thyroid nodule, 1 with history of thyroid cancer., 3 with primary hypothyroidism.
bIncluding 43 under sodium valproate, 11 under lamotrigine, 8 under oxcarbazepine, 1 under topiramate
cIncluding 54 under Quetiapine, 21 under olanzapine, 7 under aripiprazole, 5 under parpiperazone, 3 under risperdone, 2 under clozapine, 2 under amisulpride, 2 under haloperidol, 1 under ziprasidone,
dIncluding 12 under escitalopram, 9 under venlafaxine, 7 under paroxetine, 3under duloxetine, 5 under fluoxetine,. 4 under fluvoxamine, 3 under mitrazapine, 5 under sertraline, 6 under escitalopram, 2 under bupropion,
Comparison of fast serum levels of FT3, FT4, and TSH between RC and NRC
| FT3 (mean ± SD) | FT4 (mean ± SD) | TSH (mean ± SD) | ||||
|---|---|---|---|---|---|---|
| dRCBD ( | 4.9 ± 1.7 | 19.0 ± 15.4 | 3.2 ± 7.5 | 0.982g | 0.313g | 0.251g |
| Non-RCBD ( | 4.9 ± 0.9 | 16.7 ± 4.7 | 1.9 ± 1.6 | 0.030h | < 0.001h | < 0.001h |
| eRCBD ( | 4.7 ± 0.9 | 19.3 ± 16.0 | 2.1 ± 1.4 | 0.982g | 0.313g | 0.251g |
| Non-RCBD( | 4.9 ± 0.9 | 16.6 ± 4.7 | 1.9 ± 1.5 | 0.56h | < 0.002h | < 0.792h |
| fRCBD ( | 5.0 ± 0.7 | 17.0 ± 3.0 | 1.7 ± 1.0 | 0.842g | 0.702g | 0.705g |
| Non-RCBD ( | 5.1 ± 1.0 | 17.6 ± 5.7 | 1.9 ± 1.9 | 0.894h | 0.592h | 0.485h |
RCBD Rapid cycling bipolar disorder
aFor FT3
bFor FT4
cFor TSH
dIncluding all the patients
eExcluding patients with comorbidity of thyroid diseases
fExcluding patients under pyschopharmaceutical treatment within 3 months prior to recruitment or with comorbidity of thyroid diseases
gTest for equality of means
hTest for equality of variance
Fig. 1The prevalence of hypothyroidism and hyperthyroidism in bipolar disorder
Fig. 2The prevalence of TPO-abs and Tg-abs positivity in bipolar disorder